Maynard Um
-
-
-
-
-
-
-
Vanda launches NEREUS motion sickness drug after 40-year gap
-
-
-
-
-
-
-
FDA grants Vanda formal hearing on HETLIOZ jet lag application
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Misses Q4 EPS by 83c, provides guidance
-
-
-
-
-
-
-
Vanda submits FDA application for rare skin disorder drug
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 17c ; Offers Guidance
-
-
-
-
-
-
-
Cantor Biotech industry report, buying value in RevGens
-
422,386 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

